Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

Completed · Phase 4

Conditions studied: Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding

In brief

The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.

Key facts

Study ID

NCT01747746

Run by

Cook County Health

People needed

33

Starts

2012-10-01

Expected to finish

2014-10-01

Last updated by the study team

2015-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with non-valvular atrial fibrillation requiring electrical cardioversion o Atrial fibrillation of unknown duration

You may not qualify if…

• Patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by CHADS2 score ≥ 1
• Significant renal dysfunction (CrCl <15mL/min)
• Significant hepatic dysfunction (Childs-Pugh Class B or C)
• History of coagulopathy
• Active bleeding
• Hypersensitivity to Rivaroxaban
• Concomitant use of anticoagulants
• Concomitant use of potent CYP3A4/P-gp inhibitors or inducers
• Interventions requiring interruption of therapy
• Pregnancy
• Age <18 y/o
• History of GI Bleed

Where it is running

• Cook County Hospital — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.